story of the week
Measurable Residual Disease Response in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
J. Clin. Oncol 2021 Dec 15;[EPub Ahead of Print], KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, JS Garcia, CD DiNardo, V Vorobyev, NS Fracchiolla, SP Yeh, JH Jang, M Ozcan, K Yamamoto, A Illes, Y Zhou, M Dail, B Chyla, J Potluri, H DöhnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.